Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D

Eli Lilly wants you to know that it is determined to lose its rep as a last-place finisher in the race to get new blockbusters to the market. And the pharma giant is signaling that the R&D group is looking for more drugs it can bring in to complete a promised surge in new drug approvals over the next 5 years.